Insight into the application of nicotinamide mononucleotide (NMN) to age-related disorders

Abstract

Numerous animal studies have shown that the decrease in the tissue Nicotinamide Adenine Dinucleotide (NAD+) levels during aging are closely related to age-related physiological decline and that the administration of NAD+ precursors restore NAD+ levels and promotes health and prolongs lifespan. Therefore, in order to demonstrate whether NAD+ supplementation by NAD+ precursors mitigate age-related physiological dysfunction including muscle weakness in older men. We conducted a placebo-controlled, randomized, double-blind, parallel-group study in which Nicotinamide mononucleotide (NMN) was administered to healthy older men for 12 weeks. In this commentary, we overview reported human NAD+-related clinical trials including our NMN study.